Search results
- (-) Remove Press releases filter Press releases
Oxford BioMedica plc Management and Board change
Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceuti
Oxford BioMedica: Clinical Trial Update
Oxford, UK – 3 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceuti
Oxford BioMedica Interim Management Statement
Oxford, UK – 16 May 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceuti
Oxford BioMedica Announces Update from ARVO 2013
- UshStat® video selected to showcase theme of “Life-changing Research” --
Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration
Oxford, UK – 1 May 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmace
Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Mesothelioma
-- First patient treated at Velindre Cancer Centre, Wales (UK) --
Oxford BioMedica: Notice of Preliminary Results Results date: 27 February 2013
Oxford, UK – 23 January 2013: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcin
Oxford BioMedica Announces Exercise of Option by ImaginAb
-- ImaginAb acquires exclusive worldwide licence for 5T4-based imaging diagnostic --
Oxford BioMedica Announces Ocular Clinical Programme Update
-- Positive DSMB review of first patient cohort in UshStat® Phase I/IIa Study --